GAMP Software Categories Explained: What Each Category Means for Pharma Validation

GAMP categories 1, 3, 4, and 5 determine validation effort for pharmaceutical software. Classification depends on configurability, not just complexity.

GAMP Software Categories Explained: What Each Category Means for Pharma Validation
Written by TechnoLynx Published on 08 May 2026

Four categories, four levels of validation effort

The GAMP 5 framework classifies pharmaceutical software into categories that determine the appropriate level of validation effort. The classification is based on two factors: the software’s configurability (how much the user can customise its behaviour) and its complexity (how much custom development is involved). Higher categories require more documentation and more thorough testing.

Category 2 (firmware) was removed in the current GAMP 5 edition — firmware is now classified under Category 1 (infrastructure) or Category 3 (non-configured products) depending on its role.

Category 1 — Infrastructure software

Infrastructure software provides the computing environment on which GxP applications run. This includes operating systems, database management systems, middleware, virtualisation platforms, and network firmware. Category 1 systems are not GxP applications themselves, but they support GxP applications.

Validation approach: Installation qualification (IQ) — verify correct installation and configuration. No functional testing of the infrastructure software itself (the vendor is responsible for that). Document the version, patch level, and configuration settings.

Examples: Windows Server, Red Hat Enterprise Linux, Oracle Database, VMware ESXi, Docker runtime, NVIDIA CUDA drivers.

Category 3 — Non-configured products

Software used exactly as delivered by the vendor, without user configuration of business logic or workflow. The user installs it and uses it within its intended purpose.

Validation approach: Verify that the software is used within its intended scope. Review vendor documentation. Test critical functions relevant to the intended use. Do not test generic vendor functionality that is not relevant to your application.

Examples: Scientific calculators, standard analytical instruments with embedded firmware, simple data loggers, reference databases.

Category 4 — Configured products

Commercial software configured by the user to meet specific business requirements. The software functionality exists in the product; the user enables, configures, or customises features to match their process.

Validation approach: Document the configuration. Test configured features against requirements. Verify that configuration changes produce the intended behaviour. Leverage vendor testing for core functionality; user testing focuses on the configured aspects.

Examples: SAP (GxP modules), LabWare LIMS, Emerson DeltaV, Siemens SIMATIC, Veeva Vault Quality.

Category 5 — Custom applications

Software developed specifically for the intended use. This includes both fully custom-built applications and significant customisations to commercial platforms that involve writing new code.

Validation approach: Full lifecycle validation — requirements specification, design documentation, code review, unit testing, integration testing, system testing, user acceptance testing. Complete traceability from requirements through test evidence.

Examples: Custom manufacturing control systems, bespoke analytical data processing tools, ML models trained on facility-specific data, custom integration middleware.

The AI classification challenge

ML models trained on company data are Category 5 custom applications — even if they use a commercial framework (TensorFlow, PyTorch). The framework itself is Category 1 infrastructure. The pre-trained model architecture may be Category 3 or 4. The training pipeline, training data, and resulting model weights are Category 5.

Understanding how these categories apply to AI/ML systems in detail is covered in the GAMP 5 classification guide for AI/ML software, which addresses the practical challenges of multi-category classification and continuous validation for non-deterministic systems.

The practical rule

Classify accurately. Validate proportionately. A Category 4 system validated as Category 5 wastes engineering resources. A Category 5 system validated as Category 4 creates regulatory exposure. The purpose of classification is to determine the right level of effort — not the maximum level of effort.

How do GAMP categories apply to AI and machine learning systems?

AI and ML systems present a classification challenge for the GAMP framework because they do not fit neatly into the existing categories. Traditional GAMP categorisation assumes that software behaviour is deterministic and fully specified — Category 5 (custom) software is validated by testing every specified requirement. ML models produce outputs that depend on training data and may vary with model updates, complicating the “test every requirement” approach.

The pragmatic classification approach we recommend: treat the ML model as a Category 5 component within a larger system. The training pipeline, the inference pipeline, and the decision logic surrounding the model are custom software that can be validated using standard GAMP Category 5 methods. The model itself is validated through performance qualification — demonstrating that it meets predefined acceptance criteria (accuracy, sensitivity, specificity) on a representative test dataset.

Change control for ML systems requires additional considerations. Model retraining produces a new model version that must be re-validated against the acceptance criteria. Automated retraining pipelines must include validation gates: the new model is deployed only if it passes the predefined performance criteria on the validation dataset.

This approach has been accepted by FDA inspectors in several audits we have supported. The key is documentation: clearly define what the model does, how it was trained, what data it was trained on, what performance criteria it must meet, and how ongoing performance is monitored. Inspectors are not opposed to AI in pharma — they require evidence that the AI system is understood, controlled, and monitored with the same rigour as any other GxP-critical system.

GAMP Software Categories: How to Classify Pharmaceutical Systems for Validation

GAMP Software Categories: How to Classify Pharmaceutical Systems for Validation

8/05/2026

GAMP classifies software as Category 1, 3, 4, or 5 based on complexity and configurability. AI/ML systems challenge traditional category boundaries.

GAMP Guide for Validation of Automated Systems: What It Covers and How to Apply It

GAMP Guide for Validation of Automated Systems: What It Covers and How to Apply It

8/05/2026

The GAMP guide provides a risk-based framework for validating automated systems in pharma. The Second Edition extends guidance to AI, agile, and cloud.

GAMP 5 Guidelines: How to Apply Risk-Based Validation to Pharma Software

GAMP 5 Guidelines: How to Apply Risk-Based Validation to Pharma Software

8/05/2026

GAMP 5 provides a risk-based framework for validating pharmaceutical software. The Second Edition extends this to AI and machine learning systems.

EU GMP Annex 11: What It Requires for Computerised Systems in Pharma

EU GMP Annex 11: What It Requires for Computerised Systems in Pharma

7/05/2026

EU GMP Annex 11 governs computerised systems in pharma manufacturing. Its data integrity, validation, and access control requirements are specific.

Drug Manufacturing: How Pharmaceutical Production Works and Where AI Adds Value

Drug Manufacturing: How Pharmaceutical Production Works and Where AI Adds Value

7/05/2026

Drug manufacturing transforms APIs into finished products through formulation, processing, and packaging. AI improves process control, inspection, and.

Continuous Manufacturing in Pharma: How It Works and Why AI Is Essential

Continuous Manufacturing in Pharma: How It Works and Why AI Is Essential

7/05/2026

Continuous pharma manufacturing replaces batch processing with real-time flow. AI-based process control is essential for maintaining quality in continuous.

Computer System Validation in Pharma: What Engineering Teams Need to Implement

Computer System Validation in Pharma: What Engineering Teams Need to Implement

7/05/2026

Computer system validation in pharma requires documented evidence of fitness for use. CSA now offers a risk-based alternative to full CSV for lower-risk.

cGMP vs GMP: What the Difference Means for Pharmaceutical Manufacturing

cGMP vs GMP: What the Difference Means for Pharmaceutical Manufacturing

6/05/2026

cGMP is the FDA's evolving standard for manufacturing quality. GMP is the broader WHO/EU framework. The 'current' modifier changes what compliance means.

cGMP in Pharmaceutical Manufacturing: What the Regulations Actually Require

cGMP in Pharmaceutical Manufacturing: What the Regulations Actually Require

6/05/2026

cGMP pharmaceutical regulations define minimum quality standards for drug manufacturing. Compliance requires documentation, process control, and personnel.

Automated Visual Inspection in Pharma: How CV Systems Replace Manual Quality Checks

Automated Visual Inspection in Pharma: How CV Systems Replace Manual Quality Checks

6/05/2026

Automated visual inspection in pharma uses computer vision to detect defects in vials, syringes, and tablets — faster and more consistently than human.

Aseptic Manufacturing in Pharma: Process Control, Risks, and Where AI Fits

Aseptic Manufacturing in Pharma: Process Control, Risks, and Where AI Fits

6/05/2026

Aseptic manufacturing prevents microbial contamination during sterile drug production. AI monitoring addresses the environmental control gaps humans miss.

Computer Vision in Pharmacy Retail: Inventory Tracking, Planogram Compliance, and Shrinkage Reduction

Computer Vision in Pharmacy Retail: Inventory Tracking, Planogram Compliance, and Shrinkage Reduction

5/05/2026

CV in pharmacy retail addresses unique challenges: regulated product tracking, controlled substance security, and planogram compliance across thousands of SKUs.

AI-Driven Pharma Compliance: From Manual Documentation to Continuous Validation

5/05/2026

AI shifts pharma compliance from periodic manual audits to continuous automated validation — catching deviations in hours instead of months.

AI Enables Real-Time Monitoring of Aseptic Filling Lines — Here's What's Changing

5/05/2026

New AI-driven monitoring systems detect contamination risk in aseptic filling by analysing environmental and process data continuously rather than via batch sampling.

AI in Pharmaceutical Supply Chains: Where Computer Vision and Predictive Analytics Deliver ROI

5/05/2026

Pharma supply chain AI delivers measurable ROI in three areas: serialisation verification, cold-chain anomaly prediction, and visual inspection automation.

MLOps Consulting: When to Engage, What to Expect, and How to Avoid Dependency

5/05/2026

MLOps consulting should transfer capability, not create dependency. The exit criteria matter more than the entry scope.

GxP Regulations Explained: What They Mean for AI and Software in Pharma

5/05/2026

GxP is a family of regulations — GMP, GLP, GCP, GDP — each applying different validation requirements to AI systems depending on lifecycle role.

MLOps News Roundup: What Platform Consolidation Means for Engineering Teams

4/05/2026

MLOps tooling is consolidating around integrated platforms. The operational complexity shifts from integration to configuration and governance.

Pharma POC Methodology That Survives Downstream GxP Validation

2/05/2026

A pharma AI POC that survives GxP validation: five instrumentation choices made at week one, removing the 6–9 month re-derivation at validation handover.

MLOps for Organisations That Have Never Operationalised a Model

27/04/2026

MLOps keeps AI models working after deployment. Start with monitoring, versioning, and retraining pipelines — not full platform adoption.

What It Takes to Move a GenAI Prototype into Production

27/04/2026

A working GenAI prototype is not production-ready. It still needs evaluation pipelines, guardrails, cost controls, latency optimisation, and monitoring.

How to Choose an AI Agent Framework for Production

26/04/2026

Agent frameworks differ on observability, tool integration, error recovery, and readiness. LangGraph, AutoGen, and CrewAI target different needs.

EU GMP Annex 11 Requirements for Computerised Systems in Pharmaceutical Manufacturing

25/04/2026

Annex 11 governs computerised systems in EU pharma manufacturing. Its data integrity requirements and AI implications are more specific than teams assume.

How to Classify and Validate AI/ML Software Under GAMP 5 in GxP Environments

24/04/2026

GAMP 5 categories were designed for deterministic software. AI/ML systems require the Second Edition's risk-based approach and continuous validation.

How Computer Vision Replaces Manual Visual Inspection in Pharmaceutical Quality Control

23/04/2026

CV-based pharma QC inspection is a production engineering problem, not a model accuracy problem. It requires data, validation, and pipeline design.

How to Architect a Modular Computer Vision Pipeline for Production Reliability

22/04/2026

A production CV pipeline is a system architecture problem, not a model accuracy problem. Modular design enables debugging and component-level maintenance.

Proven AI Use Cases in Pharmaceutical Manufacturing Today

22/04/2026

Pharma manufacturing AI is deployable now — process control, visual inspection, deviation triage. The approach is assessment-first, not technology-first.

What GxP Compliance Actually Requires for AI Software in Pharmaceutical Manufacturing

21/04/2026

GxP applies to AI software that affects product quality, safety, or data integrity — not to every system in a pharma facility. The boundary matters.

The Real Cost of Pharmaceutical Batch Failure and How AI Prevents It

21/04/2026

Pharmaceutical batch failures cost waste, rework, and regulatory exposure. AI-based process control prevents the failure classes behind most rejections.

Why Pharma Companies Delay AI Adoption — and What It Costs Them

20/04/2026

Pharma AI adoption stalls from regulatory misperception, scope inflation, and transformation assumptions. Each delay has a measurable manufacturing cost.

When to Use CSA vs Full CSV for AI Systems in Pharma

20/04/2026

CSA and full CSV are different validation approaches for AI in pharma. The right choice depends on system risk, not regulatory habit.

GPU Computing for Faster Drug Discovery

7/01/2026

GPU computing in drug discovery: how parallel workloads accelerate molecular simulation, docking calculations, and deep learning models for compound property prediction.

The Role of GPU in Healthcare Applications

6/01/2026

Where GPUs are essential in healthcare AI: medical image processing, genomic workloads, and real-time inference that CPU-only architectures cannot sustain at production scale.

AI Transforming the Future of Biotech Research

16/12/2025

AI in biotech research: how machine learning accelerates compound screening, genomic analysis, and experimental design decisions in biological research pipelines.

AI and Data Analytics in Pharma Innovation

15/12/2025

Machine learning in pharma: applying biomarker analysis, adverse event prediction, and data pipelines to regulated pharmaceutical research and development workflows.

AI in Rare Disease Diagnosis and Treatment

12/12/2025

AI for rare disease diagnosis: how small dataset constraints shape model selection, transfer learning strategies, and the clinical validation requirements.

Visual analytic intelligence of neural networks

7/11/2025

Neural network visualisation: how activation maps, layer inspection, and feature attribution reveal what a model has learned and where it will fail.

MLOps for Hospitals - Staff Tracking (Part 2)

9/12/2024

Hospital staff tracking system, Part 2: training the computer vision model, containerising for deployment, setting inference latency targets, and configuring production monitoring.

MLOps for Hospitals - Building a Robust Staff Tracking System (Part 1)

2/12/2024

Building a hospital staff tracking system with computer vision, Part 1: sensor setup, data collection pipeline, and the MLOps environment for training and iteration.

AI in Pharmaceutics: Automating Meds

28/06/2024

Artificial intelligence is without a doubt a big deal when included in our arsenal in many branches and fields of life sciences, such as neurology, psychology, and diagnostics and screening. In this article, we will see how AI can also be beneficial in the field of pharmaceutics for both pharmacists and consumers. If you want to find out more, keep reading!

The Synergy of AI: Screening & Diagnostics on Steroids!

3/05/2024

Computer vision in medical imaging: how AI systems accelerate screening and diagnostic workflows while managing the false-positive rates that determine clinical acceptance.

Retrieval Augmented Generation (RAG): Examples and Guidance

23/04/2024

Learn about Retrieval Augmented Generation (RAG), a powerful approach in natural language processing that combines information retrieval and generative AI.

Back See Blogs
arrow icon